Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for stubborn eczema? abrocitinib tested after biologics fail

NCT ID NCT06899204

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure improvements in skin symptoms and itching at 16 weeks. This is an observational study, meaning patients receive standard care, and no new treatments are being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abrocitinib (Cibinqo)
What this could lead to
If successful, this study could show that abrocitinib is an effective option for people with stubborn eczema who haven't gotten relief from biologic drugs.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It's also relatively small (150 people) and only follows patients for 16 weeks, so long-term benefits or risks aren't fully assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ATOPIC DERMATITIS, UNSPECIFIED DERMATITIS, ATOPIC

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allergy and Asthma Medical Group and Research Center

    RECRUITING

    San Diego, California, 92123, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.